{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:07Z","timestamp":1791976507156,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaad.2023.12.065","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:35:38Z","timestamp":1705797338000},"page":"986-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe D.","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Guenthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zirwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.12.065_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1468-3083.2011.04079.x","article-title":"Seborrheic dermatitis: lifetime detection rates","volume":"26","author":"Palamaras","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.12.065_bib2","series-title":"Patient and healthcare provider perspectives on the disease burden of seborrheic dermatitis in the United States: results from a national survey","author":"Chovatiya","year":"2023"},{"key":"10.1016\/j.jaad.2023.12.065_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1590\/0101-60830000000106","article-title":"Personality traits and common psychiatric conditions in patients with seborrheic dermatitis","volume":"44","author":"G\u00fcl","year":"2017","journal-title":"Arch Clin Psychiatry"},{"key":"10.1016\/j.jaad.2023.12.065_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0001-7310(07)70111-4","article-title":"Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis","volume":"98","author":"Peyr\u00ed","year":"2007","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaad.2023.12.065_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1439-0507.2008.01624.x","article-title":"Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level","volume":"52","author":"Szepietowski","year":"2009","journal-title":"Mycoses"},{"key":"10.1016\/j.jaad.2023.12.065_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/exd.14091","article-title":"An update on the microbiology, immunology and genetics of seborrheic dermatitis","volume":"29","author":"Adalsteinsson","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.01.001","article-title":"Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies","volume":"31","author":"Dessinioti","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib8","first-page":"24","article-title":"Seborrheic dermatitis in skin of color: clinical considerations","volume":"18","author":"Elgash","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib9","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1074\/jbc.R200029200","article-title":"Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling","volume":"278","author":"Conti","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2023.12.065_bib10","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.116.232819","article-title":"Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes","volume":"358","author":"Dong","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2023.12.065_bib12","series-title":"ZORYVE (roflumilast) cream prescribing information","year":"2022"},{"key":"10.1016\/j.jaad.2023.12.065_bib13","series-title":"Long-term safety and efficacy of roflumilast foam 0.3% in patients with seborrheic dermatitis in a 24\u201352-week, open-label phase 2 trial","author":"Alexis","year":"2022"},{"key":"10.1016\/j.jaad.2023.12.065_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamadermatol.2023.0846","article-title":"Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase 2a randomized clinical trial","volume":"159","author":"Zirwas","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.12.065_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ijd.12645","article-title":"The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis","volume":"54","author":"Naegeli","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2006.01.011","article-title":"Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation","volume":"54","author":"High","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.12.065_bib25","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jid.2022.05.602","article-title":"Krafft temperature of surfactants in vehicles for roflumilast and pimecrolimus cream and effects on skin tolerability","volume":"142","author":"Berk","year":"2022","journal-title":"J Investig Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224001075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224001075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:01:12Z","timestamp":1717606872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224001075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0190962224001075"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.12.065","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.12.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}